ResearcherSanford USD Medical CenterActive in the last 2 years

Steven Francis Powell

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5029-0048; OpenAlex author ID A5073432388. Sources: OpenAlex.

Their work

Papers: 3
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 13

Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 3

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Alexander Grenander Raufi · 1 shared paper, 2025 · strength 0.19
- Paper Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in pre… DOI 10.1016/j.esmoop.2025.105122 ↗
Benedito A. Carneiro · 1 shared paper, 2025 · strength 0.19
- Paper Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in pre… DOI 10.1016/j.esmoop.2025.105122 ↗
Marisol Huerta · 1 shared paper, 2025 · strength 0.19
- Paper Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in pre… DOI 10.1016/j.esmoop.2025.105122 ↗
Ludimila L. Cavalcante · 1 shared paper, 2025 · strength 0.19
- Paper Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in pre… DOI 10.1016/j.esmoop.2025.105122 ↗
Andrès M.R. Cervantes · 1 shared paper, 2025 · strength 0.19
- Paper Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in pre… DOI 10.1016/j.esmoop.2025.105122 ↗
Devalingam Mahalingam · 1 shared paper, 2025 · strength 0.19
- Paper Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in pre… DOI 10.1016/j.esmoop.2025.105122 ↗
Andrew L. Coveler · 1 shared paper, 2025 · strength 0.19
- Paper Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in pre… DOI 10.1016/j.esmoop.2025.105122 ↗
Anwaar Saeed · 1 shared paper, 2025 · strength 0.19
- Paper Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in pre… DOI 10.1016/j.esmoop.2025.105122 ↗
Jordan D. Berlin · 1 shared paper, 2025 · strength 0.19
- Paper Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in pre… DOI 10.1016/j.esmoop.2025.105122 ↗
Vaibhav Sahai · 1 shared paper, 2025 · strength 0.19
- Paper Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in pre… DOI 10.1016/j.esmoop.2025.105122 ↗
Mary F. Mulcahy · 1 shared paper, 2025 · strength 0.19
- Paper Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in pre… DOI 10.1016/j.esmoop.2025.105122 ↗
Gary L Timmerman · 1 shared paper, 2020 · strength 0.09
- Paper Implementation of a standardized approach to borderline resectable pancreatic cancer in a multisite community oncology … DOI 10.1016/j.sopen.2020.07.003 ↗
Jonathan Scott Bleeker · 1 shared paper, 2020 · strength 0.09
- Paper Implementation of a standardized approach to borderline resectable pancreatic cancer in a multisite community oncology … DOI 10.1016/j.sopen.2020.07.003 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.